Trials / Unknown
UnknownNCT05029973
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
A Study to Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in Unresectable Hepatocellular Carcinoma.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HAIC | hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment |
| DRUG | Sintilimab | 200mg IV d1,Q3W |
| DRUG | Bevacizumab Biosimilar | 7.5mg/kg IV d1,Q3W |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2022-01-10
- Completion
- 2023-11-10
- First posted
- 2021-09-01
- Last updated
- 2023-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05029973. Inclusion in this directory is not an endorsement.